Sharekhan

Aarti Drugs Ltd

Wed 30/04/2025,15:59:54 | NSE : AARTIDRUGS

₹ 349.00-1.80 (-0.51%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 357.60

Previous Close

₹ 350.80

Volume

244406

Mkt Cap ( Rs. Cr)

₹3185.32

High

₹ 361.90

Low

₹ 345.25

52 Week High

₹ 635.00

52 Week Low

₹ 312.00

Book Value Per Share

₹ 139.96

Dividend Yield

0.28

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Aarti Drugs Ltd

Your Vote -

Buy

51.83%

Hold

27.24%

Sell

20.92%

51.83%

1472 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

349.00

341

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

341

Option Chain

Analyzes market sentiment, predicts Aarti Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2025, 10:45PM Aarti Drugs Limited has informed the Exchange about Schedule of meet
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Apr 2025, 10:43PM Intimation of Quarterly Earning Conference Call
  • Aarti Drugs Ltd - Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended March 31, 2025

    29 Apr 2025, 7:19PM Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 ,inter alia, to consider and appr
  • Aarti Drugs Ltd - Board Meeting Intimation

    29 Apr 2025, 7:10PM AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 06-May-2025 to inter-alia consider and approve the Audited Financial r
  • Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    18 Apr 2025, 8:30PM As of March 2025, 55.48% is owned by Indian Promoters and 44.52% by Public. <p align=justify> Institutional holds 11.95% (Insurance Companies 0.08%) a
  • Aarti Drugs Ltd - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2025, 11:47AM Aarti Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Aarti Drugs Ltd - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2025, 11:43AM Certificate under Re. 74(5) of SEBI (DP) Regulations, 2018
  • Aarti Drugs Ltd - Action(s) taken or orders passed

    2 Apr 2025, 3:54PM Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed
  • Aarti Drugs Ltd - Disclosure Under Regulation 30 Of SEBI Listing Regulations

    2 Apr 2025, 3:53PM Disclosure under Regulation 30 of SEBI Listing Regulations - Cautionary letter from Stock Exchange.
  • Aarti Drugs Ltd - Trading Window-XBRL

    29 Mar 2025, 2:57PM AARTI DRUGS LIMITED has informed the Exchange about Closure of Trading Window
  • Aarti Drugs Ltd - Trading Window

    29 Mar 2025, 2:56PM Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Mar 2025, 6:13PM Aarti Drugs Limited has informed the Exchange about Schedule of meet
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Mar 2025, 6:09PM Intimation of Schedule of Analyst / Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Mar 2025, 7:46PM Aarti Drugs Limited has informed the Exchange about Cancellation of Schedule of Analyst / Institutional Investor Meetings.
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Mar 2025, 7:36PM Cancellation of Schedule of Analyst / Institutional Investor Meetings.
  • Aarti Drugs Ltd - Action(s) taken or orders passed

    7 Mar 2025, 12:46PM Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed
  • Aarti Drugs Ltd - Action(s) taken or orders passed

    6 Mar 2025, 8:20PM Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed
  • Aarti Drugs Ltd - Announcement Under Regulation 30 Of Listing Regulations - ESG Rating

    3 Mar 2025, 7:40PM Announcement under Regulation 30 of Listing Regulation - ESG Rating
  • Aarti Drugs Ltd - General Updates

    3 Mar 2025, 7:39PM Aarti Drugs Limited has informed the Exchange about General Updates
  • Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Feb 2025, 6:31PM Aarti Drugs Limited has informed the Exchange about Schedule of meet
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    28 Feb 2025, 6:25PM Intimation of Schedule of Analyst / Institutional Investor Meetings
  • Aarti Drugs Ltd - Disclosure Under Reg 30 Of Listing Regulations - Update On Lifting Of Import Alert 66-40 By US DFA

    14 Feb 2025, 3:10PM Disclosure under Reg 30 of Listing Regulations - Update on lifting of Import Alert 66-40 by US FDA
  • Aarti Drugs Ltd - Action(s) taken or orders passed

    14 Feb 2025, 3:10PM Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed
  • Aarti Drugs Ltd - Disclosure Under Regulation 30 Of Listing Reguations- Order Of CGST And C.Ex. Authority

    7 Feb 2025, 8:09PM Disclosure under Regulation 30 of Listing Regulations - Order of CGST and C.Ex. Authority
  • Aarti Drugs Ltd - Action(s) taken or orders passed

    7 Feb 2025, 8:09PM Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed
  • Aarti Drugs Ltd - Disclosure Under Regulation 30 Of Listing Regulations-

    5 Feb 2025, 9:48PM Disclosure under Regulation 30 of Listing Regulations
  • Aarti Drugs Ltd - Action(s) taken or orders passed

    5 Feb 2025, 9:48PM Aarti Drugs Limited has informed the Exchange about Action(s) taken or orders passed
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    4 Feb 2025, 10:26PM Q3FY25 Earnings call transcript
  • Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2025, 10:26PM Aarti Drugs Limited has informed the Exchange about Transcript
  • Aarti Drugs Ltd - General Updates

    4 Feb 2025, 3:05PM Aarti Drugs Limited has informed the Exchange about General Updates
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Acquisition

    4 Feb 2025, 3:04PM Announcement dated February 3, 2025 regarding Disclosure under Regulation 30 of Listing Regulations
  • Aarti Drugs Ltd - Acquisition-XBRL

    3 Feb 2025, 3:39PM AARTI DRUGS LIMITED has informed the Exchange regarding Acquisition
  • Aarti Drugs Ltd - General Updates

    3 Feb 2025, 3:37PM Aarti Drugs Limited has informed the Exchange about General Updates
  • Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Acquisition

    3 Feb 2025, 3:37PM Entering into Share Subscription and Shareholder's Agreement for Power Purchase
  • ICRA reaffirms ratings of Aarti Drugs

    16 Apr 2021 , 2:39PM Credit ratings firm ICRA has reaffirmed its credit rating on the commercial paper
  • Aarti Drugs board approves buyback worth up to Rs. 60 crore

    19 Mar 2021 , 3:12PM Aarti Drugs’ board approves share buyback worth up to Rs 60 cr at Rs 1,000/sh
  • Aarti Drugs to consider share buyback on March 19

    16 Mar 2021 , 9:36AM Intimation for buyback of the fully paid-up equity shares of the Company
  • Aarti Drugs

    8 Mar 2021 , 9:42AM Fully owned subsidiary company - Aarti Specialty Chemicals has received approval under the Government of India’s PLI scheme for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum Target Segment III (Key Chemical Synthesis Based KSMs/Drug Intermediates). The rate incentive will be 10 % of sales value per annum for a period of 6 years starting FY23 to FY28. This is positive as it would enable diversification of product portfolio and also enhance the revenues and profitability.
  • Aarti Drugs

    22 Sep 2020 , 11:56AM The company has set October 1, 2020 as the record date for the company's bonus issue. The board had approved a bonus issue of 3:1 in August 2020.
  • Aarti Drugs fixes record date for bonus issue

    22 Sep 2020 , 10:31AM Record date for issue of bonus shares
  • Aarti Drugs board recommends bonus issue

    20 Aug 2020 , 2:14PM Aarti Drugs board approves issuing 3 bonus equity shares for every 1 fully paid-up equity share held
  • Aarti Drugs surges in flat market

    17 Aug 2020 , 11:30AM Board to consider Bonus Issue
  • Aarti Drugs falls in strong market

    12 Mar 2018 , 1:01PM Aarti Drugs slips over 6% at Rs527.75, after company announces its unit in Tarapur MIDC got affected by explosion
  • Aarti Drugs gains on fixing record date for buyback

    9 Jan 2018 , 11:41AM Aarti Drugs surges over 7% at Rs784.8, after company fixes January 19, 2018 as record date for buyback shares

Key fundamentals

Evaluate the intrinsic value of Aarti Drugs Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 1648.0593 1647.387 1487.0525 1149.3541 952.6836
Liabilities 1648.0593 1647.387 1487.0525 1149.3541 952.6836
Equity 91.935 92.6 92.6 93.2 23.3
Gross Profit 266.1306 282.4035 318.1833 401.2687 244.4082
Net Profit 141.8827 152.8109 194.9982 257.7124 135.6747
Cash From Operating Activities 337.1041 162.2824 39.896 154.0754 196.1475
NPM(%) 6.25 6.11 8.66 13.45 8.29
Revenue 2266.9114 2497.9704 2251.1743 1914.8903 1634.922
Expenses 2000.7808 2215.5669 1932.991 1513.6216 1390.5138
ROE(%) 11.1 11.96 15.26 20.17 10.62

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
04 Feb 2025 1 10 0.29 396.7
06 Feb 2024 1 10 0.29 535.25
08 Feb 2023 1 10 0.29 410.15
09 Feb 2022 1 10 0.29 503.45
03 Nov 2020 2.5 25 0.29 750.3
17 Feb 2020 2 20 0.29 628.3
26 Jul 2019 1 10 0.29 602.7
01 Aug 2018 1 10 0.29 566.8
09 Aug 2017 1 10 0.29 482.4
22 Mar 2016 3 30 0.29 492.9
12 Feb 2016 1.5 15 0.29 527.5
10 Nov 2015 2.25 22.5 0.29 582.65
05 Aug 2015 3 30 0.29 738.6
04 Feb 2015 5 50 0.29 1051.2
19 Nov 2014 5 50 0.29 756.6
02 Jul 2014 5.5 55 0.29 357.7
05 Feb 2014 4.5 45 0.29 217.55
19 Nov 2013 3 30 0.29 193.2
24 Jul 2013 4 40 0.29 190.55
11 Feb 2013 3 30 0.29 221
05 Nov 2012 3 30 0.29 176.15
17 Aug 2012 3 30 0.29 100.9
06 Feb 2012 2 20 0.29 89.15
14 Jul 2011 2.5 25 0.29 128.65
07 Feb 2011 2.5 25 0.29 139.05
18 Aug 2010 5 50 0.29 118.1
23 Jul 2009 3 30 0.29 50.8
13 Aug 2008 1.8 18 0.29 51.75
20 Mar 2007 1.2 12 0.29 56.45
19 Jul 2006 1.5 15 0.29 88.7
27 Jul 2005 1.6 16 0.29 127.65
25 Jun 2004 1.8 18 0.29 79.25
13 Nov 2003 1.2 12 0.29 96.8
23 Oct 2001 0 10 0.29 17.5
11 Jun 2001 0 15 0.29 15.3
0 8 0.29 25.95
0 7 0.29 33.35
0 7 0.29 19
0 11 0.29 13.5
0 22 0.29 11.55

Peers

Other companies within the same industry or sector that are comparable to Aarti Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 825.75 -1.80 11.65 199.04 1321.50 1.39
Lotus Eye Hospital and Institute Ltd 81.22 -0.17 338.42 725.27 14.01 0.62
Vaishali Pharma Ltd 13.47 -1.82 449.00 373.83 2.76 0.00
Astec Lifesciences Ltd 685.90 -1.03 0.00 683.87 -687.11 0.00

Company Info

Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1. 2020 -The Company has issued Bonus Shares in the Ratio of 3:1. 2023 -Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22"". 2024 -The Company Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra"".

Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1. 2020 -The Company has issued Bonus Shares in the Ratio of 3:1. 2023 -Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22"". 2024 -The Company Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra"".

Read More

Parent Organisation

Aarti Drugs Ltd.

Founded

28/09/1984

Managing Director

Mr.Rashesh C Gogri

NSE Symbol

AARTIDRUGSEQ

FAQ

The current price of Aarti Drugs Ltd is ₹ 349.00.

The 52-week high for Aarti Drugs Ltd is ₹ 361.90 and the 52-week low is ₹ 345.25.

The market capitalization of Aarti Drugs Ltd is currently ₹ 3185.32. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Aarti Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Aarti Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Aarti Drugs Ltd shares.

The CEO of Aarti Drugs Ltd is Mr.Rashesh C Gogri, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT